Moomoo AI 已提取核心信息
On February 2, 2024, ProSomnus, Inc., a Delaware corporation, filed a post-effective amendment to its Form S-1 on Form S-3 with the Securities and Exchange Commission (SEC). This filing is intended to convert the previously filed Registration Statement on Form S-1 into a registration statement on Form S-3. The original Registration Statement was declared effective by the SEC on December 14, 2023. The amendment does not register any additional securities and states that all applicable registration and filing fees were paid during the original filing. The prospectus included in the amendment details a secondary offering of up to 44,913,872 shares of common stock, which may be issued upon the exercise of warrants, the conversion of Series A Preferred Stock, as dividends on the Series A Preferred Stock, and upon conversion of convertible notes. ProSomnus, Inc. is a company specializing in the manufacture of precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea. The company's common stock is listed on the Nasdaq Global Market under the symbol 'OSA'.
On February 2, 2024, ProSomnus, Inc., a Delaware corporation, filed a post-effective amendment to its Form S-1 on Form S-3 with the Securities and Exchange Commission (SEC). This filing is intended to convert the previously filed Registration Statement on Form S-1 into a registration statement on Form S-3. The original Registration Statement was declared effective by the SEC on December 14, 2023. The amendment does not register any additional securities and states that all applicable registration and filing fees were paid during the original filing. The prospectus included in the amendment details a secondary offering of up to 44,913,872 shares of common stock, which may be issued upon the exercise of warrants, the conversion of Series A Preferred Stock, as dividends on the Series A Preferred Stock, and upon conversion of convertible notes. ProSomnus, Inc. is a company specializing in the manufacture of precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea. The company's common stock is listed on the Nasdaq Global Market under the symbol 'OSA'.
2024年2月2日，特拉华州的一家公司ProSomnus, Inc. 向美国证券交易委员会（SEC）提交了S-3表格S-1的生效后修正案。本文件旨在将先前在表格S-1上提交的注册声明转换为表格S-3上的注册声明。美国证券交易委员会于2023年12月14日宣布最初的注册声明生效。该修正案没有登记任何其他证券，并规定所有适用的注册和申请费都是在最初的申报期间支付的。修正案中包含的招股说明书详细说明了最多44,913,872股普通股的二次发行，可以在行使认股权证、将A系列优先股转换为A系列优先股的股息以及转换可转换票据时发行。Prosomnus, Inc. 是一家专门生产用于治疗阻塞性睡眠呼吸暂停的精密、大规模定制口服器械治疗设备的公司。该公司的普通股在纳斯达克全球市场上市，股票代码为 “OSA”。
2024年2月2日，特拉华州的一家公司ProSomnus, Inc. 向美国证券交易委员会（SEC）提交了S-3表格S-1的生效后修正案。本文件旨在将先前在表格S-1上提交的注册声明转换为表格S-3上的注册声明。美国证券交易委员会于2023年12月14日宣布最初的注册声明生效。该修正案没有登记任何其他证券，并规定所有适用的注册和申请费都是在最初的申报期间支付的。修正案中包含的招股说明书详细说明了最多44,913,872股普通股的二次发行，可以在行使认股权证、将A系列优先股转换为A系列优先股的股息以及转换可转换票据时发行。Prosomnus, Inc. 是一家专门生产用于治疗阻塞性睡眠呼吸暂停的精密、大规模定制口服器械治疗设备的公司。该公司的普通股在纳斯达克全球市场上市，股票代码为 “OSA”。
有用
没用